Other Transaction Agreement W911QY2190011
Award Date
12/4/20
Potential Completion Date
7/29/22
Potential Value
$5.7M
Funding Federal Agency
Joint PEO Chemical and Biological Defense
Contracting Federal Agency
ACC Aberdeen Proving Ground
Awardee
60 Degrees Pharmaceuticals, Inc.
Ultimate Awardee
Not listed
NAICS Category
Not listed
PSC Category
AC13 - National Defense R&D Services; Department Of Defense - Military; Experimental Development
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Competed
Major Defense Program
Not listed
Pricing Type
Other
Place of Performance
Washington, DC 20036, USA
Solicitation Procedures
Broad Agency Announcement
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $54.5 million other transaction agreement to Inovio Pharmaceuticals, Inc. to support the development of an electroporation device for COVID-19 prototype efforts. Performance will take place in Plymouth Meeting, Pennsylvania over a two-year period concluding in June 2022. The contract was awarded without any set aside designations to the prime contractor Inovio Pharmaceuticals to develop...
The U.S. Department of Defense's Joint Program Executive Office for Chemical and Biological Defense awarded a $29,929,031.81 Other Transaction Agreement to Just-Evotec Biologics, Inc. to produce monoclonal antibody (mAb) product countermeasures against COVID-19. The contract, awarded on January 15, 2021, has an ultimate completion date of June 30, 2022 and is not set aside for any special business categories. Just-Evotec Biologics, Inc. is a for-profit, foreign-owned manufacturer of goods.
Just-Evotec Biologics, Inc., doing business as Just-Evotec Biologics, has been awarded a $17.9 million other transaction agreement by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to support the production of monoclonal antibody (mAb) countermeasures against COVID-19. The contract will run from July 2020 through February 2022 and will be performed in Seattle, Washington. Under the agreement, Just-Evotec Biologics will leverage its expertise in...
This federal contract award, W911QY2190008, was issued by the Joint PEO Chemical and Biological Defense, a subcomponent of the U.S. Department of the Army, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The $62,096,250.00 Other Transaction Agreement is for the development of a "COVID-19" Monoclonal Antibody (MAB) Sponsorship Prototype. Resilience Government Services, a technology-focused biomanufacturing company, has previously received federal...
The Department of the Army Medical Command awarded Ophirex, Inc. a $10.6 million definitive contract to support research and development efforts for a COVID-19 treatment under the Small Business Innovation Research Program Phase III. The prime contractor will conduct work at its place of performance in Corte Madera, California from June 2020 through September 2023 under the firm fixed price contract, which has a total small business set aside designation. Specifically, Ophirex will perform...
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $766,254 purchase order to ANP Technologies Inc. to develop Lightweight Field Instruments in support of the Coronavirus COVID-19 national interest. The firm fixed price contract will be performed in Newark, Delaware through May 31, 2020. No subcontractors or set aside designations were identified. The award provides urgently needed equipment to the Chemical and Biological Defense program's...
The Department of the Army Medical Command awarded a $47.2 million other transaction order to Medical Technology Enterprise Consortium (MTEC) for a COVID-19 prototype project. Under contract number 20-10-COVID-19-NETCCN-TATRC, MTEC will deliver prototype products and services to support the Army's COVID-19 response efforts through March 2024. The place of performance is Summerville, South Carolina. As the prime contractor for this other transaction order placed under the larger Network-Centric...
This is a $12,549,999,847.50 Definitive Contract awarded by the U.S. Army Contracting Command - Aberdeen Proving Ground, Natick Division on behalf of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the Biomedical Advanced Research and Development Authority (BARDA) to Pfizer Inc. for the delivery of 10 million treatment courses of the oral protease inhibitor PF-07321332. This contract, which does not utilize a small business...
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded an Other Transaction Agreement to Emergent Biosolutions Canada Inc. valued at $34.6 million to support the development of human immune globulin (COVID-HIG) manufactured from human plasma with antibodies to SARS-CoV-2. The contract aims to prevent coronavirus disease (COVID-19) through October 2022. Performance will take place at Emergent Biosolutions Canada Inc.'s facility in Ottawa,...
<p>The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense (DOD - Army - USASC) awarded an $8.66 billion definitive contract to Pfizer Inc., doing business as Pfizer, for COVID-19 Adult MDV Vaccine. The contract is a firm fixed price agreement with a place of performance in New York, NY. The period of performance spans from June 29, 2022 through February 29, 2024. No subcontractors were identified.</p>